首页> 外文OA文献 >Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial.
【2h】

Automated Risk Assessment for Stroke in Atrial Fibrillation (AURAS-AF)--an automated software system to promote anticoagulation and reduce stroke risk: study protocol for a cluster randomised controlled trial.

机译:心房颤动中风​​的自动风险评估(AURAS-AF)-促进抗凝和降低中风风险的自动化软件系统:一项针对群集随机对照试验的研究方案。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BACKGROUND: Patients with atrial fibrillation (AF) are at significantly increased risk of stroke. Oral anticoagulants (OACs) substantially reduce this risk, with gains seen across the spectrum of baseline risk. Despite the benefit to patients, OAC prescribing remains suboptimal in the United Kingdom (UK). We will investigate whether an automated software system, operating within primary care electronic medical records, can improve the management of AF by identifying patients eligible for OAC therapy and increasing uptake of this treatment. METHODS/DESIGN: We will conduct a cluster randomised controlled trial, involving general practices using the Egton Medical Information Systems (EMIS) Web clinical system. We will randomise practices to use an electronic software tool or to continue with usual care. The tool will a) produce (and continually refresh) a list of patients with AF who are eligible for OAC therapy--practices will invite these patients to discuss therapy at the start of the trial--and b) generate electronic screen reminders in the medical records of those eligible, appearing throughout the trial. The software will run for 6 months in 23 intervention practices. A total of 23 control practices will manage their AF register in line with the usual care offered. The primary outcome is change in proportion of eligible patients with AF who have been prescribed OAC therapy after six months. Secondary outcomes are incidence of stroke, transient ischaemic attack, other major thromboembolism, major haemorrhage and reports of inappropriate OAC prescribing in the data collection sample--those deemed eligible for OACs. We will conduct a process evaluation in parallel with the randomised trial. We will use qualitative methods to examine patient and practitioner views of the intervention and its impact on primary care practice, including its time implications. DISCUSSION: AURAS-AF will investigate whether a simple intervention, using electronic primary care records, can improve OAC uptake in a high risk group for stroke. Given previous concerns about safety, especially surrounding inappropriate prescribing, we will also examine whether electronic reminders safely impact care in this clinical area. TRIAL REGISTRATION: http://ISRCTN 55722437.
机译:背景:房颤(AF)患者的中风风险显着增加。口服抗凝剂(OAC)大大降低了这种风险,并且在整个基线风险范围内均获得了收益。尽管对患者有益,但OAC处方在英国(UK)仍然不是最佳选择。我们将调查在初级保健电子病历中运行的自动化软件系统是否可以通过确定有资格接受OAC治疗的患者并增加对该治疗的吸收来改善房颤的管理。方法/设计:我们将使用Egton医学信息系统(EMIS)Web临床系统进行一项包括一般常规在内的整群随机对照试验。我们将随机分配使用电子软件工具的惯例或继续进行常规护理。该工具将a)生成(并不断刷新)有资格进行OAC治疗的AF患者的列表-实践将邀请这些患者在试验开始时讨论治疗方法,并且b)生成电子屏幕提醒在整个试验过程中出现符合条件者的病历。该软件将在23种干预措施中运行6个月。共有23种控制措施将按照提供的日常护理措施管理其AF寄存器。主要结局是六个月后接受OAC治疗的合格AF患者的比例变化。次要结果是中风的发生率,短暂性脑缺血发作,其他严重的血栓栓塞,严重的出血以及数据收集样本中OAC处方不当的报道-被认为符合OAC资格的人。我们将与随机试验同时进行过程评估。我们将使用定性方法来检查患者和医生对干预措施及其对初级保健实践的影响(包括时间影响)的观点。讨论:AURAS-AF将研究使用电子基层医疗记录进行的简单干预是否可以改善中风高危人群的OAC摄取。鉴于先前对安全性的担忧,尤其是围绕不适当处方的担忧,我们还将研究电子提醒是否会安全地影响该临床领域的护理。试用注册:http:// ISRCTN 55722437。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号